性能参数

产品名称

Omaveloxolone (RTA-408)

规格

5mg 25mg

货号

GOY-Y2649

 含量

>98.00%

CAS

1474034-05-3

别名

N/A

化学名

N/A

分子式

C33H44F2N2O3

分子量

分子量 554.71

溶解度

≥ 55.5mg/mL in DMSO, ≥ 25.05mg/mL in EtOH

储存条件

Store at -20°C

General tips

用途

仅供科研

价格

电询

详细内容

RTA-408 is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.

To evaluate the anti-inflammatory activity of RTA-408, RAW 264.7 mouse macrophage cells are treated with RTA-408 for two hours and then IFNγ is added to stimulate NO production and release into the media. RTA-408 dose-dependently reduces NO concentrations in the media with an IC50 value of 4.4±1.8 nM. The potency of RTA-408 in this assay is similar to that of Bardoxolone methyl, which has an IC50 value of 1.9±0.8 nM. Nrf2 activation is required for AIM-mediated NO suppression. A decrease in nitric oxide synthase 2 (Nos2) protein levels is observed in bardoxolone methyl-treated RAW 264.7 cells, which is attenuated when Nrf2 mRNA levels are reduced by siRNA. To evaluate the anticancer activity of RTA-408, a panel of eight human cell lines derived from tumors of different origin are treated with RTA-408 and measured cell growth 72 hours later using the sulforhodamine B (SRB) assay. RTA-408 inhibits the growth of all tumor lines with an average GI50 value of 260±74 nM. To determine whether RTA-408 induces apoptosis, the panel of tumor cells are treated with RTA-408 and the caspase substrate, DEVD-AFC, for 24 hours. RTA-408 dose-dependently increases DEVD-AFC cleavage, indicating that RTA-408 treatment triggers caspase activation in cancer cells. Caspase-3 and caspase-9 cleavage is also observed by western blot at the same concentrations of RTA-408 that increases DEVD-AFC cleavage[1].

To determine whether RTA-408 is an effective mitigator of hematopoietic acute radiation syndrome after bone marrow-lethal doses of total-body irradiation (TBI), mice are administered 3 daily injections of 17.5 mg/kg RTA-408 beginning 24 h after TBI. Teatment with RTA-408 results in the 35 day survival of 100% of 7 Gy (LD40/35) TBI mice (P<0.05) and 60% of 7.5 Gy (LD100/13) TBI mice (P<0.0001)[2].

三氯甲烷标准溶液 基体：甲醇  乙醇标准溶液 0.80mg/mL，基体：水

三氯甲烷 农残级, ≥99.8%（剧毒品）  铕标准溶液 1000μg/mL in 10%HCL

三氯甲烷 Standard for GC  乙二胺四乙酸(EDTA)二钠纯度标准物质 99.96%

氯化亚铜 AR，97%  乙基汞标准溶液 75.3×10-6

硫酸铜，五水 99.99% metals basis  环氧氯丙烷标准溶液 997.8mg/L,溶剂:二氯甲烷

硫酸铜，五水 细胞培养级, ≥98%  柠檬黄标准溶?

N-3-oxo-butyryl-L-Homoserine lactone1 mg 5 mg 10 mg>95.00%Cas No. 148433-27-6C8H11NO4

N-3-hydroxybutyryl-L-Homoserine lactone1mg 5mg 10mg>95.00%Cas No. 1325550-06-8C8H13NO4

N-desethyl Amodiaquine (hydrochloride)500μg 1mg 5mg>95.00%Cas No. 79049-30-2C18H18ClN3O?2HCl

Nerolidol10g 25g 50g>95.00%Cas No. 7212-44-4C15H26O

Neospiramycin I1 mg 5 mg 10 mg>95.00%Cas No. 70253-62-2C36H62N2O11

Norwogonin1mg 5mg 10mg>95.00%Cas No. 9/8/4443C15H10O5

L-Lysine lactam (hydrochloride)50 mg 100 mg 500 mg 1 g>95.00%Cas No. 26081-07-2C6H12N2O.HCl